Cyrano Therapeutics
Latest round
- Series B
Last raised
- Dec 2023
Total raised
- $19M
Investors
- 3
About Cyrano Therapeutics
, operates as a pharmaceutical company that develops therapeutic solutions for olfactory dysfunction, a condition that limits the ability to taste and smell. In November 2020, Cyrano Therapeutics, Inc. The company offers regenerative medicine for loss of smell and flavor function. The company has created a proprietary intranasal product to help patients with chronic loss of taste and smell regain function. The company is working to determine an optimal dose and validate the therapy in a double-blind, randomized setting.
Who invested in Cyrano Therapeutics
3 investors across 2 rounds
See all investors in Cyrano Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cyrano Therapeutics
Who invested in Cyrano Therapeutics?
Cyrano Therapeutics has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cyrano Therapeutics raised?
Cyrano Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cyrano Therapeutics last raise money?
Cyrano Therapeutics's most recent round on record is a Series B, in Dec 2023.
What does Cyrano Therapeutics do?
, operates as a pharmaceutical company that develops therapeutic solutions for olfactory dysfunction, a condition that limits the ability to taste and smell.
Where is Cyrano Therapeutics headquartered?
Cyrano Therapeutics is headquartered in US.
Which VCs invest in companies like Cyrano Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cyrano Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Cyrano Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.